Antibacterial macrolides: A drug class with a complex pharmacological profile

Pharmacological Research

Volumn 50, Issue 3, 2004, Pages 211-222

  Abu Gharbieh, Eman ^a   Vasina, Valentina ^a   Poluzzi, Elisabetta ^a   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Drug metabolism; Drug safety; Macrolides; Motilin; QT prolongation

Indexed keywords

AMOXICILLIN; AMPRENAVIR; ANTIINFECTIVE AGENT; AZITHROMYCIN; CISAPRIDE; CLARITHROMYCIN; DIRITHROMYCIN; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; FLURITHROMYCIN; JOSAMYCIN; MACROLIDE; METRONIDAZOLE; MIDAZOLAM; MIDECAMYCIN; MIOKAMYCIN; MOTILIN; NIFEDIPINE; OLEANDOMYCIN; PENICILLIN G; PROKINETIC AGENT; RECEPTOR; RITONAVIR; ROKITAMYCIN; ROXITHROMYCIN; SIMVASTATIN; SPIRAMYCIN; TELITHROMYCIN; TROLEANDOMYCIN; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIOSTASIS; DIARRHEA; DRUG APPROVAL; DRUG BINDING; DRUG EFFECT; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; ELECTROCARDIOGRAM; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HEART ARRHYTHMIA; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HUMAN; HYPOKALEMIA; ITALY; LIVER TOXICITY; NAUSEA; NONHUMAN; OTOTOXICITY; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; RISK; RISK FACTOR; SKIN ALLERGY; STRUCTURE ACTIVITY RELATION; TORSADE DES POINTES; UNITED KINGDOM; UNITED STATES; VOMITING;

EID: 3042587916     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2004.01.008     Document Type: Article

References (146)

1. Shaheen N., Grimm I.S. Fulminant hepatic failure associated with clarithromycin. Am. J. Gastroenterol. 91:1996;394-395
2. Kolkman W., Groeneveld J.H., Baur H.J., Verschuur H.P. Ototoxicity induced by clarithromycin. Ned Tijdschr Geneeskd. 146:2002;1743-1745
3. Bizjak E.D., Haug M.T. III, Schilz R.J., Sarodia B.D., Dresing J.M. Intravenous azithromycin-induced ototoxicity. Pharmacotherapy. 19:1999;245-248
4. Schonwald S., Gunjaca M., Kolacny-Babic L., Car V., Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J. Antimicrob. Chemother. 25(Suppl. A):1990;123-126
5. Gangemi S., Ricciardi L., Fedele R., Isola S., Purello-D'Ambrosio F. Immediate reaction to clarithromycin. Allergol. Immunopathol. (Madr.). 29:2001;31-32
6. Kruppa A., Scharffetter-Kochanek K., Krieg T., Hunzelmann N. Immediate reaction to roxithromycin and prick test cross-sensitization to erythromycin and clarithromycin. Dermatology. 196:1998;335-336
7. Dietz A., Hubner C., Andrassy K. Macrolide antibiotic-induced vasculitis (Churg-Strauss syndrome). Laryngorhinootologie. 77:1998;111-114
8. Igea J.M., Lazaro M. Hypersensitivity reaction to clarithromycin. Allergy. 53:1998;107-109
9. Gallardo M.A., Thomas I. Hypersensitivity reaction to erythromycin. Cutis. 64:1999;375-376
10. Peeters T.L. Erythromycin and other macrolides as prokinetic agents. Gastroenterology. 105:1993;1886-1899
11. Blondeau J.M., DeCarolis E., Metzler K.L., Hansen G.T. The macrolides. Expert Opin. Invest. Drugs. 11:2002;189-215
12. Shain C.S., Amsden G.W. Telithromycin: the first of the ketolides. Ann. Pharmacother. 36:2002;452-464
13. Zhanel G.G., Walters M., Noreddin A., Vercaigne L.M., Wierzbowski A., Embil J.M., et al. The ketolides: a critical review. Drugs. 62:2002;1771-1804
14. Lea A.P., Lamb H.M. Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women. Pharmacoeconomics. 12:1997;596-611
15. Jones RN, Pfaller MA, Cormican MG. Infectious diseases (bacterial and fungal). Avery's Drug Treatment 1997:1454-514.
16. Lacey R.W., Lord V.L., Howson G.L. In-vitro evaluation of miokamycin: bactericidal activity against streptococci. J. Antimicrob. Chemother. 13:1984;5-13
17. Hardy D.J., Hensey D.M., Beyer J.M., Vojtko C., McDonald E.J., Fernandes P.B. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob. Agents Chemother. 32:1988;1710-1719
18. Hardy D.J., Hanson C.W., Hensey D.M., Beyer J.M., Fernandes P.B. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J. Antimicrob. Chemother. 22:1988;631-636
19. Soussy C.J., Leclercq R., Duval J. In vitro antibacterial activity of a new macrolide: miokamycin. Comparison with erythromycin and josamycin. Pathol. Biol. (Paris). 36:1988;370-376
20. Weiss K., De Azavedo J., Restieri C., Galarneau L.A., Gourdeau M., Harvey P., et al. Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec-Canada. J. Antimicrob. Chemother. 47:2001;345-348
21. Chambers HF. Antimicrobial agents, protein synthesis and miscellanous antibacterial agents. In: Goodman and Gilman's the pharmacological basis of therapeutics, 2001. p. 1239-71.
22. Itoh Z., Suzuki T., Nakaya M., Inoue M., Mitsuhashi S. Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrob. Agents Chemother. 26:1984;863-869
23. Zara G.P., Thompson H.H., Pilot M.A., Ritchie H.D. Effects of erythromycin on gastrointestinal tract motility. J. Antimicrob. Chemother. 16(Suppl. A):1985;175-179
24. Itoh Z., Nakaya M., Suzuki T., Arai H., Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am. J. Physiol. 247:1984;G688-G694
25. Bruley Des Varannes S., Parys V., Ropert A., Chayvialle J.A., Roze C., Galmiche J.P. Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology. 109:1995;32-39
26. Curry J.I., Lander T.D., Stringer M.D. Erythromycin as a prokinetic agent in infants and children. Aliment Pharmacol. Ther. 15:2001;595-603
27. Cucchiara S., Minella R., Scoppa A., Emiliano M., Calabrese F., Az-Zeqeh N., et al. Antroduodenal motor effects of intravenous erythromycin in children with abnormalities of gastrointestinal motility. J. Pediatr. Gastroenterol. Nutr. 24:1997;411-418
28. Zatman T.F., Hall J.E., Harmer M. Gastric residual volume in children: a study comparing efficiency of erythromycin and metoclopramide as prokinetic agents. Br. J. Anaesth. 86:2001;869-871
29. Sifrim D., Janssens J., Vantrappen G. Effect of midecamycin acetate on gastrointestinal motility in humans. Int. J. Clin. Pharmacol. Res. 12:1992;71-79
30. Itoh Z., Suzuki T., Nakaya M., Inoue M., Arai H., Wakabayashi K. Structure-activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract. Am. J. Physiol. 248:1985;G320-G325
31. Omura S., Tsuzuki K., Sunazuka T., Marui S., Toyoda H., Inatomi N., et al. Macrolides with gastrointestinal motor stimulating activity. J. Med. Chem. 30:1987;1941-1943
32. Itoh Z., Omura S. Motilide, a new family of macrolide compounds mimicing motilin. Dig. Dis. Sci. 32:1987;915
33. Peeters T., Matthijs G., Depoortere I., Cachet T., Hoogmartens J., Vantrappen G. Erythromycin is a motilin receptor agonist. Am. J. Physiol. 257:1989;G470-G474
34. Stanghellini V., De Ponti F., De Giorgio R., Barbara G., Tosetti C., Corinaldesi R. New developments in the treatment of functional dyspepsia. Drugs. 63:2003;869-892
35. Peeters TL. Motilide. In: Katholieke Universiteit Leuven; 2002. Available at http://www.kuleuven.ac.be/gih/motilid.htm, last accessed on: 2-7-2003.
36. Lartey P.A., Nellans H.N., Faghih R., Petersen A., Edwards C.M., Freiberg L., et al. Synthesis of 4″-deoxy motilides: identification of a potent and orally active prokinetic drug candidate. J. Med. Chem. 38:1995;1793-1798
37. Cowles V.E., Nellans H.N., Seifert T.R., Besecke L.M., Segreti J.A., Mohning K.M., et al. Effect of novel motilide ABT-229 versus erythromycin and cisapride on gastric emptying in dogs. J. Pharmacol. Exp. Ther. 293:2000;1106-1111
38. Verhagen M.A., Samsom M., Maes B., Geypens B.J., Ghoos Y.F., Smout A.J. Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol. Ther. 11:1997;1077-1086
39. Sifrim D., Missotten T., Depoortere I., Peeters T.L., Janssens J. The motilide ABT-229 increases feline lower esophageal sphincter pressure by activating neural motilin receptors. Dig. Dis. Sci. 41:1996;1891
40. De Ponti F., Malagelada J.R. Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management. Pharmacol. Ther. 80:1998;49-88
41. Costa A., De Ponti F., Gibelli G., Crema F., d'Angelo L. In vivo characterization of the colonic prokinetic effect of erythromycin in the rabbit. Pharmacology. 54:1997;64-75
42. von Rosensteil N.A., Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf. 13:1995;105-122
43. Jameson J.S., Rogers J., Misiewicz J.J., Raimundo A.H., Henry M.M. Oral or intravenous erythromycin has no effect on human distal colonic motility. Aliment Pharmacol. Ther. 6:1992;589-595
44. Smith A.J., Nissan A., Lanouette N.M., Shi W., Guillem J.G., Wong W.D., et al. Prokinetic effect of erythromycin after colorectal surgery: randomized, placebo-controlled, double-blind study. Dis. Colon Rectum. 43:2000;333-337
45. Depoortere I., Peeters T.L., Vantrappen G. Motilin receptors of the rabbit colon. Peptides. 12:1991;89-94
46. Sharma S.S., Bhargava N., Mathur S.C. Effect of oral erythromycin on colonic transit in patients with idiopathic constipation. A pilot study. Dig. Dis. Sci. 40:1995;2446-2449
47. Tack J., Peeters T. What comes after macrolides and other motilin stimulants? Gut. 49:2001;317-318
48. Camilleri M. Motilin agonists and dyspepsia: throwing out the baby with the bath water. Gut. 51:2002;612-613
49. Talley N.J., Verlinden M., Geenen D.J., Hogan R.B., Riff D., McCallum R.W., et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut. 49:2001;395-401
50. Van Herwaarden M.A., Samsom M., Van Nispen C.H., Verlinden M., Smout A.J. The effect of motilin agonist ABT-229 on gastro-oesophageal reflux. Aliment Pharmacol. Ther. 14:2000;453-462
51. Anti-infectives systemic. In: Facts and comparisons. Drug facts and comparisons. St. Louis; 2003. p. 1300-11.
52. Hopkins S. Clinical toleration and safety of azithromycin. Am. J. Med. 91:1991;40S-45S
53. Ng P.C., So K.W., Fung K.S., Lee C.H., Fok T.F., Wong E., et al. Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants. Arch. Dis. Child Fetal Neonatal. Ed. 84:2001;F177-F182
54. Simkiss D.E., Adams I.P., Myrdal U., Booth I.W. Erythromycin in neonatal postoperative intestinal dysmotility. Arch. Dis. Child. 71:1994;F128-F129
55. Miller S.M., O'Dorisio T.M., Thomas F.B., Mekhjian H.S. Erythromycin exerts a prokinetic effect in patients with chronic idiopathic intestinal pseudo-obstruction. Gastroenterology. 98:1990;A375
56. Heidenreich A., Wille S., Hofmann R. Gastroparesis after retroperitoneal surgery successfully treated with erythromycin. J. Urol. 163:2000;545
57. Klutman N.E., Eisenach J.B. Erythromycin therapy for gastroparesis. South Med. J. 85:1992;524-527
58. Richards R.D., Davenport K., Hurm K.D., Wimbish W.R., McCallum R.W. Acute and chronic treatment of gastroparesis with erythromycin. Gastroenterology. 98:1990;A385
59. Richards R.D., Davenport K., McCallum R.W. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am. J. Gastroenterol. 88:1993;203-207
60. Douthwaite S., Champney W.S. Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J. Antimicrob. Chemother. 48(Suppl. T1):2001;1-8
61. Volberg W.A., Koci B.J., Su W., Lin J., Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. 302:2002;320-327
62. Promphan W., Khongphatthanayothin A., Horchaiprasit K., Benjacholamas V. Roxithromycin induced torsade de pointes in a patient with complex congenital heart disease and complete atrioventricular block. Pacing Clin. Electrophysiol. 26:2003;1424-1426
63. Fazekas T., Krassoi I., Lengyel C., Varro A., Papp J.G. Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine. Pacing Clin. Electrophysiol. 21:1998;147-150
64. Morey T.E., Martynyuk A.E., Napolitano C.A., Raatikainen M.J., Guyton T.S., Dennis D.M. Ionic basis of the differential effects of intravenous anesthetics on erythromycin-induced prolongation of ventricular repolarization in the guinea pig heart. Anesthesiology. 87:1997;1172-1181
65. Rubart M., Pressler M.L., Pride H.P., Zipes D.P. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation. 88:1993;1832-1844
66. Daleau P., Lessard E., Groleau M.F., Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation. 91:1995;3010-3016
67. Abbott G.W., Sesti F., Splawski I., Buck M.E., Lehmann M.H., Timothy K.W., et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 97:1999;175-187
68. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology. Cardiovasc. Res. 58:2003;32-45
69. Giner Almaraz S., Canòs Cabedo M., Rodilla Calvelo F., Ferrer Gòmez C. Nuevous macrolidos ¿Superan a eritromicina? Farm Hosp. 19:1995;259-265
70. Periti P., Mazzei T., Mini E., Novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin. Pharmacokinet. 16:1989;193-214
71. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J. Antimicrob. Chemother. 37(Suppl C):1996;133-142
72. Desta Z., Kerbusch T., Flockhart D.A. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin. Pharmacol. Ther. 65:1999;10-20
73. Yeates R.A., Laufen H., Zimmermann T., Schumacher T. Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin. Int. J. Clin. Pharmacol. Ther. 35:1997;577-579
74. Ouellet D., Hsu A., Granneman G.R., Carlson G., Cavanaugh J., Guenther H., et al. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin. Pharmacol. Ther. 64:1998;355-362
75. Brophy D.F., Israel D.S., Pastor A., Gillotin C., Chittick G.E., Symonds W.T., et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob. Agents Chemother. 44:2000;978-984
76. Bruce M.A., Hall S.D., Haehner-Daniels B.D., Gorski J.C. In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab. Dispos. 29:2001;1023-1028
77. McConnell S.A., Amsden G.W. Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin. Pharmacotherapy. 19:1999;404-415
78. Ohtani H., Taninaka C., Hanada E., Kotaki H., Sato H., Sawada Y., et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob. Agents Chemother. 44:2000;2630-2637
79. Stramba-Badiale M., Guffanti S., Porta N., Frediani M., Beria G., Colnaghi C. QT interval prolongation and cardiac arrest during antibiotic therapy with spiramycin in a newborn infant. Am. Heart J. 126:1993;740-742
80. Osservatorio Nazionale sull'impiego dei medicinali. L'uso dei farmaci in Italia - Rapporto nazionale anno 2002.
81. Minami T., Nishibayashi H., Shinomura Y., Matsuzawa Y. Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J. Gastroenterol. 31:1996;855-859
82. Hill A.D., Walsh T.N., Hamilton D., Freyne P., O'Hare N., Byrne P.J., et al. Erythromycin improves emptying of the denervated stomach after oesophagectomy. Br. J. Surg. 80:1993;879-881
83. Altomare D.F., Rubini D., Pilot M.A., Farese S., Rubini G., Rinaldi M., et al. Oral erythromycin improves gastrointestinal motility and transit after subtotal but not total gastrectomy for cancer. Br. J. Surg. 84:1997;1017-1021
84. Petrakis J., Vassilakis J.S., Karkavitsas N., Tzovaras G., Epanomeritakis E., Tsiaoussis J., et al. Enhancement of gastric emptying of solids by erythromycin in patients with Roux-en-Y gastrojejunostomy. Arch. Surg. 133:1998;709-714
85. Stacher G., Peeters T.L., Bergmann H., Wiesnagrotzki S., Schneider C., Granser-Vacariu G.V., et al. Erythromycin effects on gastric emptying. Gut. 34:1993;166-172
86. Stewart J.J., Wood M.J., Parish R.C., Wood C.D. Prokinetic effects of erythromycin after antimotion sickness drugs. J. Clin. Pharmacol. 40:2000;347-353
87. Chen J., Yeaton P., McCallum R.W. Effect of erythromycin on gastric myoelectrical activity in normal human subjects. Am. J. Physiol. 263:1992;G24-G28
88. Koutsoumbi P., Epanomeritakis E., Tsiaoussis J., Athanasakis H., Chrysos E., Zoras O., et al. The effect of erythromycin on human esophageal motility is mediated by serotonin receptors. Am. J. Gastroenterol. 95:2000;3388-3392
89. Chiba T., Thomforde G.M., Kost L.J., Allen R.G., Phillips S.F. Motilides accelerate regional gastrointestinal transit in the dog. Aliment. Pharmacol. Ther. 14:2000;955-960
90. Nakayoshi T., Izumi M., Tatsuta K. Effects of macrolide antibiotics on gastrointestinal motility in fasting and digestive states. Drugs Exp. Clin. Res. 18:1992;103-109
91. Mathis C., Malbert C.H. Gastric but not duodenal motor effects of oral erythromycin are dose related. Neurogastroenterol. Motil. 7:1995;47-54
92. Ringger N.C., Lester G.D., Neuwirth L., Merritt A.M., Vetro T., Harrison J. Effect of bethanechol or erythromycin on gastric emptying in horses. Am. J. Vet. Res. 57:1996;1771-1775
93. Kaufman H.S., Ahrendt S.A., Pitt H.A., Lillemoe K.D. The effect of erythromycin on motility of the duodenum, sphincter of Oddi, and gallbladder in the prairie dog. Surgery. 114:1993;543-548
94. Roussel A.J., Hooper R.N., Cohen N.D., Bye A.D., Hicks R.J., Bohl T.W. Prokinetic effects of erythromycin on the ileum, cecum, and pelvic flexure of horses during the postoperative period. Am. J. Vet. Res. 61:2000;420-424
95. Kounenis G., Koutsoviti-Papadopoulou M., Elezoglou V. Comparative study of erythromycin, troleandomycin and tylosin on the rabbit intestine. Fundam. Clin. Pharmacol. 8:1994;173-177
96. Weber F.H.J., Richards R.D., McCallum R.W. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am. J. Gastroenterol. 88:1993;485-490
97. Lartey P.A., Nellans H.N., Tanaka S.K. New developments in macrolides: structures and antibacterial and prokinetic activities. Adv. Pharmacol. 28:1994;307-343
98. Siani M.A., Skillman A.G., Carreras C.W., Ashley G., Kuntz I.D., Santi D.V. Development and screening of a polyketide virtual library for drug leads against a motilide pharmacophore. J. Mol. Graph Model. 18:2000;497-540
99. Bortolotti M., Brunelli F., Sarti P., Mari C., Miglioli M. Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Aliment Pharmacol. Ther. 12:1998;1021-1025
100. Sifrim D., Janssens J., Vantrappen G. Comparison of the effects of midecamycin acetate and clarithromycin on gastrointestinal motility in man. Drugs Exp. Clin. Res. 18:1992;337-342
101. Sifrim D., Matsuo H., Janssens J., Vantrappen G. Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man. Drugs Exp. Clin. Res. 20:1994;121-126
102. Bearden D.T., Neuhauser M.M., Garey K.W. Telithromycin: an oral ketolide for respiratory infections. Pharmacotherapy. 21:2001;1204-1222
103. Mishra A., Friedman H.S., Sinha A.K. The effects of erythromycin on the electrocardiogram. Chest. 115:1999;983-986
104. Oberg K.C., Bauman J.L. QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy. 15:1995;687-692
105. Kent S., Ferguson M., Trotta R., Jordan L. T wave alternans associated with HIV cardiomyopathy, erythromycin therapy, and electrolyte disturbances. South Med. J. 91:1998;755-758
106. Kdesh A., McPherson C.A., Yaylali Y., Yasick D., Bradley K., Manthous C.A. Effect of erythromycin on myocardial repolarization in patients with community-acquired pneumonia. South Med. J. 92:1999;1178-1182
107. Tschida S.J., Guay D.R., Straka R.J., Hoey L.L., Johanning R., Vance-Bryan K. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy. 16:1996;663-674
108. Gitler B., Berger L.S., Buffa S.D. Torsades de pointes induced by erythromycin. Chest. 105:1994;368-372
109. Hsieh M.H., Chen S.A., Chiang C.E., Tai C.T., Lee S.H., Wen Z.C., et al. Drug-induced torsades de pointes in one patient with congenital long QT syndrome. Int. J. Cardiol. 54:1996;85-88
110. Rezkalla M.A., Pochop C. Erythromycin induced Torsades de Pointes: case report and review of the literature. SDJ Med. 47:1994;161-164
111. de Koning J., van der Hoeven H., Hamer B., Thompson J. Erythromycin-induced torsades de pointes and ventricular fibrillation in a patient with Legionella pneumonia. Neth. J. Med. 44:1994;131-135
112. Brandriss M.W., Richardson W.S., Barold S.S. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review. Clin. Infect. Dis. 18:1994;995-998
113. Haefeli W.E., Schoenenberger R.A., Weiss P., Ritz R. Possible risk for cardiac arrhythmia related to intravenous erythromycin. Intensive Care Med. 18:1992;469-473
114. Lin J.C., Quasny H.A. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. Pharmacotherapy. 17:1997;626-630
115. Katapadi K., Kostandy G., Katapadi M., Hussain K.M., Schifter D. A review of erythromycin-induced malignant tachyarrhythmia - torsade de pointes. A case report. Angiology. 48:1997;821-826
116. Hondeghem L.M., Dujardin K., De Clerck F. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc. Res. 50:2001;345-353
117. Antzelevitch C., Sun Z.Q., Zhang Z.Q., Yan G.X. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J. Am. Coll. Cardiol. 28:1996;1836-1848
118. Eckardt L., Haverkamp W., Mertens H., Johna R., Clague J.R., Borggrefe M., et al. Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, D, L-sotalol, and erythromycin. J. Cardiovasc. Pharmacol. 32:1998;425-434
119. Gray V.S. Syncopal episodes associated with cisapride and concurrent drugs. Ann. Pharmacother. 32:1998;648-651
120. Wong C.B., Windle J. Erythromycin induced torsades de pointes. Nebr. Med. J. 80:1995;285-286
121. Kamochi H., Nii T., Eguchi K., Mori T., Yamamoto A., Shimoda K., et al. Clarithromycin associated with torsades de pointes. Jpn. Circ. J. 63:1999;421-422
122. Piquette R.K. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann. Pharmacother. 33:1999;22-26
123. Hayashi Y., Ikeda U., Hashimoto T., Watanabe T., Mitsuhashi T., Shimada K. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin. Electrophysiol. 22:1999;672-674
124. Choudhury L., Grais I.M., Passman R.S. Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis. 1:1999;206-207
125. Sekkarie M.A. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am. J. Kidney Dis. 30:1997;437-439
126. Kundu S., Williams S.R., Nordt S.P., Clark R.F. Clarithromycin-induced ventricular tachycardia. Ann. Emerg. Med. 30:1997;542-544
127. Vallejo C.N., Rodriguez P.D., Sanchez H.A., Tornos Mas M.P., Ribera E., Soler S.J. Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection. Rev. Esp. Cardiol. 55:2002;878-881
128. Woywodt A., Grommas U., Buth W., Rafflenbeul W. QT prolongation due to roxithromycin. Postgrad. Med. J. 76:2000;651-653
129. Stramba-Badiale M., Nador F., Porta N., Guffanti S., Frediani M., Colnaghi C., et al. QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am. Heart J. 133:1997;108-111
130. Anti-infective Drugs Advisory Committee - Food and Drug Administration Center for Drug Evaluation and Research Ketek (telithromycin). Proposed for treatment of community-acquired pneumonia, acute exacerbation of chronic bronchitis and acute maxillary sinusitis. In: Food and Drug Administration Center for Drug Evaluation and Research, 2003.
131. Westphal J.F. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin. Br. J. Clin. Pharmacol. 50:2000;285-295
132. Yasui N., Otani K., Kaneko S., Ohkubo T., Osanai T., Sugawara K., et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin. Pharmacol. Ther. 59:1996;514-519
133. Wong S.L., Cao G., Mack R.J., Granneman G.R. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J. Clin. Pharmacol. 37:1997;1056-1061
134. Al Humayyd M.S. Pharmacokinetic interactions between erythromycin, clarithromycin, roxithromycin and phenytoin in the rat. Chemotherapy. 43:1997;77-85
135. Amacher D.E., Schomaker S.J., Retsema J.A. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob. Agents Chemother. 35:1991;1186-1190
136. Greenblatt D.J., von Moltke L.L., Harmatz J.S., Counihan M., Graf J.A., Durol A.L., et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin. Pharmacol. Ther. 64:1998;278-285
137. Paar D., Terjung B., Sauerbruch T. Life-threatening interaction between clarithromycin and disopyramide. Lancet. 349:1997;326-327
138. Midoneck S.R., Etingin O.R. Clarithromycin-related toxic effects of digoxin. N. Engl. J. Med. 333:1995;1505
139. Recker M.W., Kier K.L. Potential interaction between clarithromycin and warfarin. Ann. Pharmacother. 31:1997;996-998
140. Pollak P.T., Sketris I.S., MacKenzie S.L., Hewlett T.J. Delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann. Pharmacother. 29:1995;486-488
141. Gooderham M.J., Bolli P., Fernandez P.G. Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. Ann. Pharmacother. 33:1999;796-799
142. Flockhart D.A., Drici M.D., Kerbusch T., Soukhova N., Richard E., Pearle P.L., et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J. Clin. Psychopharmacol. 20:2000;317-324
143. Kaeser Y.A., Brunner F., Drewe J., Haefeli W.E. Severe hypotension and bradycardia associated with verapamil and clarithromycin. Am. J. Health Syst. Pharm. 55:1998;2417-2418
144. Yamazaki H., Shimada T. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab. Dispos. 26:1998;1053-1057
145. Zhao X.J., Ishizaki T. An in-vitro study on the metabolism of rokitamycin and possible interactions of the drug with rat liver microsomes. J. Pharm. Pharmacol. 51:1999;1167-1174
146. De Ponti F., Poluzzi E., Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur. J. Clin. Pharmacol. 57:2001;185-209